A significant percentage of affected patients were observed to have dilated atria and left ventricular hypertrophy.
All articles by Diana Ernst, RPh
Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor.
Telmisartan, an angiotensin II receptor blocker, is indicated for the treatment of hypertension.
Twice-yearly dosing with inclisiran sodium resulted in significant lowering of low-density lipoprotein cholesterol.
Treatment with sacubitril/valsartan provides greater benefits in certain patients with HFpEF, according to analyses from the phase 3 PARAGON-HF trial.
Treatment with empagliflozin, a SGLT2 inhibitor, was associated with reduced risk of hospitalization for heart failure.
This retrospective, single-center study included 143 patients who were newly initiated on sacubitril/valsartan during their hospitalization.
Dapagliflozin significantly reduced the risk of cardiovascular death or worsening heart failure when added to standard of care treatment in patients with reduced ejection fraction.
Latest News Your top articles for TuesdayFor More Personalized News
Haymarket Medical NetworkTop Picks
Continuing Medical Education (CME/CE) Courses